| HOST SPECIES: | Mouse |
| SPECIES REACTIVITY: | Human |
| IMMUNOGEN: | CD80 antibody was raised against the extracellular domain of human CD80. |
| TESTED APPLICATIONS: | ICC, IF, IHC-P |
| APPLICATIONS: | CD80 antibody can be used for detection of CD80 by Western blot at 0.5 - 1 μg/mL. Antibody can also be used for immunohistochemistry starting at 2 - 5 μg/mL. For immunofluorescence start at 5μg/mL. Antibody validated: Western Blot in human samples; Immunohistochemistry in human samples; Immunocytochemistry in human samples; Immunofluorescence in human samples and Flow Cytometry in mouse samples. All other applications and species not yet tested. |
| POSITIVE CONTROL: | 1) Cat. No. 1340 - Human Stomach Carcinoma Tissue Lysate |
| 2) Cat. No. 1315 - Human Tonsil Tissue | |
| PREDICTED MOLECULAR WEIGHT: | Predicted: 32 kDa Observed: 50 kDa |
Specifications| PURIFICATION: | CD80 Antibody is supplied as protein A purified IgG1. |
| CLONALITY: | Monoclonal |
| ISOTYPE: | IgG1 |
| CONJUGATE: | Unconjugated |
| PHYSICAL STATE: | Liquid |
| BUFFER: | CD80 Antibody is supplied in PBS containing 0.02% sodium azide and 50% glycerol. |
| CONCENTRATION: | 1 mg/mL |
| STORAGE CONDITIONS: | CD80 antibody can be stored at 4˚C for three months and -20˚C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures. |
| OFFICIAL SYMBOL: | CD80 |
| ALTERNATE NAMES: | CD80 Antibody: CD80 molecule, B7, BB1, B7-1, B7.1, LAB7, CD28LG, CD28LG1 |
| ACCESSION NO.: | NP_005182 |
| PROTEIN GI NO.: | 4885123 |
| GENE ID: | 941 |
| USER NOTE: | Optimal dilutions for each application to be determined by the researcher. |
| BACKGROUND: | CD80 Antibody: CD80, also known as B7-1, is a type I membrane protein that is a member of the immunoglobulin superfamily. Like the related protein CD86, this protein is expressed by antigen-presenting cells, and is the ligand for two proteins at the cell surface of T cells, CD28 and the cytotoxic T-lymphocyte-associated protein 4 (CTLA-4). Binding of this protein with CD28 antigen is a costimulatory signal for activation of the T-cell and induces T-cell proliferation and cytokine production. CTLA-4 binding negatively regulates T-cell activation and diminishes the immune response (1). Blocking the CTLA-4-CD80/CD86 interaction has been shown to enhance T-cell functions in acute lymphoblastomic leukemia (ALL), suggesting that this pathway may be an attractive target for future cancer immunotherapy (2). |
| REFERENCES: | 1) Lane P. Regulation of T and B cell responses by modulating interactions between CD28/CTLA-4 and their ligands, CD80 and CD86. Ann NY Acad Sci 1997; 815:392-400. | 2) Feucht J, Kayser S, Gorodezki D, et al. T-cell responses against CD19+ pediatric acute lymphoblastic leukemia mediated by bispecific T-cell engager (BiTE) are regulated contrarily by PD-L1 and CD80/CD86 on leukemic blasts. Oncotarget 2016; 7:76902-19. |
ANTIBODIES FOR RESEARCH USE ONLY.
For additional information, visit ProSci's Terms & Conditions Page.
